Pfizer’s bipolar disorder drug Geodon receives expanded FDA approval
By APFriday, November 20, 2009
Pfizer’s Geodon gets expanded FDA approval
NEW YORK — Pfizer Inc. said Friday the Food and Drug Administration approved Geodon as a part of a combination maintenance treatment for bipolar disorder in adults.
The new approval covers use of Geodon as an adjunct to lithium or valproate.
The drug is already approved as a treatment for schizophrenia and bipolar disorder.
Shares of Pfizer rose 20 cents to $18.31 in afternoon trading.
YOUR VIEW POINT
